Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription by Yang, Lichuan et al.
Neuroprotective Effects of the Triterpenoid, CDDO
Methyl Amide, a Potent Inducer of Nrf2-Mediated
Transcription
Lichuan Yang
1, Noel Y. Calingasan
1, Bobby Thomas
1, Rajnish K. Chaturvedi
1, Mahmoud Kiaei
1,
Elizabeth J. Wille
1, Karen T. Liby
2, Charlotte Williams
2, Darlene Royce
2, Renee Risingsong
2,E r i cS .
Musiek
3, Jason D. Morrow
3, Michael Sporn
2, M. Flint Beal
1*
1Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, New York, United States of America,
2Department of Pharmacology, Dartmouth Medical School, Hanover, New Hampshire, United States of America, 3Department of Clinical Pharmacology, Vanderbilt
University Medical Center, Nashville, Tennessee, United States of America
Abstract
The NF-E2-related factor-2 (Nrf2)/antioxidant response element (ARE) signaling pathway regulates phase 2 detoxification
genes,including a variety of antioxidative enzymes. We testedneuroprotectiveeffects of the synthetic triterpenoidCDDO-MA,
a potent activator of the Nrf2/ARE signaling. CDDO-MA treatment of neuroblastoma SH-SY5Y cells resulted in Nrf2
upregulation and translocation from cytosol to nucleus and subsequent activation of ARE pathway genes. CDDO-MA blocked
t-butylhydroperoxide-induced production of reactive oxygen species (ROS) by activation of ARE genes only in wild type, but
not Nrf2 knockout mouse embryonic fibroblasts. Oral administration of CDDO-MA resulted in significant protection against
MPTP-induced nigrostriatal dopaminergic neurodegeneration, pathological alpha-synuclein accumulation and oxidative
damage in mice. Additionally, CDDO-MA treatment in rats produced significant rescue against striatal lesions caused by the
neurotoxin 3-NP, and associated increases in the oxidative damage markers malondialdehyde, F2-Isoprostanes, 8-hydroxy-2-
deoxyguanosine, 3-nitrotyrosine, and impaired glutathione homeostasis. Our results indicate that the CDDO-MA renders its
neuroprotective effects through its potent activation of the Nrf2/ARE pathway, and suggest that triterpenoids may be
beneficial for the treatment of neurodegenerative diseases like Parkinson’s disease and Huntington’s disease.
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Introduction
There is increasing evidence showing that both mitochondrial
dysfunction and oxidative damage play a key role in the
pathogenesis of neurodegenerative diseases such as Parkinson’s
disease (PD) and Huntington’s disease (HD) [1,2]. An extremely
promising pathway for neurotherapeutics is the NF-E2-related
factor-2 (Nrf2)/antioxidant response element (ARE) signaling
pathway [3–6]. The transcription factor Nrf2 is a key regulatory
factor in the coordinated induction of a battery of cytoprotective
genes, including those encoding for both antioxidant and anti-
inflammatory proteins. The induction of these protective genes
depends on the nuclear translocation of Nrf2 and its binding to the
ARE, a regulatory enhancer sequence, which is present in the
promoter region of the involved genes. The regulation of the Nrf
system involves another cytosolic protein, KEAP1 (kelch-like
ECH-associated protein 1), which binds to Nrf2 in the cytosol and
prevents its nuclear translocation and subsequent transcriptional
activation of the ARE genes [7,8]. Critical cysteine residues in the
KEAP1 protein are essential for its ability to inactivate Nrf2 by
retaining it in the cytosol. These cysteine residues are targets for
various drugs that form Michael adducts with KEAP1 [9–12].
Nrf2/ARE signaling regulates over 200 genes, including those
encoding anti-oxidative genes and detoxifying enzymes (known as
the ‘‘phase 2’’ enzymes) [13].
One critical enzyme that is induced by the Nrf2 signaling
pathway is NADPH quinone oxidoreductase-1 (NQO-1). This
enzyme is involved in detoxification of protein-bound quinone,
and it functions to maintain alpha-tocopherol and coenzyme Q10
(CoQ10) in their reduced antioxidant states. Another ARE-
dependent protein is the stress responsive inducible enzyme
hemeoxygenase-1 (HO-1). HO-1 is involved in the metabolism of
the prooxidant heme to the antioxidant pigment biliverdin, ferrous
iron and carbon monoxide [14], and it has profound anti-
inflammatory properties [15]. Two inflammatory mediators which
are downregulated by Nrf2 are inducible nitric oxide synthase
(iNOS) and the prostaglandin synthesizing cyclooxygenase 2
(COX2) [16]. Both iNOS- and COX2-deficient mice are resistant
to dopaminergic neurotoxicity in a mouse model of PD [17,18].
Experiments using Nrf2 knockout mice and primary astroglial
and neuronal cultures derived from these mice show that
disruption of Nrf2 renders neuronal tissue more susceptible to
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5757oxidative stress [19]. Conversely, Nrf2 overexpression in mixed rat
neuron-glia cortical cultures enhances antioxidant capacity in both
neuronal and astroglial cells, and protects cortical neurons from
excitotoxicity. Nrf2 deficient mice are more susceptible to 3-
nitropropionic acid (3-NP) toxicity [20]. Transplantation of Nrf2
overexpressing astrocytes protects against the toxic effects of the
mitochondrial complex 2 inhibitor malonate [21]. Transgenic
mice over-expressing Nrf2 in astrocytes are resistant to MPTP
neurotoxicity and when crossed into a transgenic mouse model of
amyotrophic lateral sclerosis they delayed disease onset and
prolonged survival [22,23].
There is, therefore, an excellent rationale for the development
of new neuroprotective agents, based on their ability to enhance
activity of Nrf2. Oleanolic acid is a naturally occurring
triterpenoid, which has been used for centuries in Asian medicine,
due to its anti-inflammatory activity. Synthetic triterpenoids such
as CDDO have been found to be potent inducers of the
transcriptional activity of Nrf2, resulting in marked induction of
NQO-1, HO-1, glutathione transferases, and other cytoprotective
enzymes, as well as suppressing induction of iNOS and COX2 at
nanomolar concentrations [9,24–29]. One of the possible
mechanisms of these triterpenoids as Nrf2 inducers is their
involvement in Michael reaction to reactive cysteine residues on
KEAP1 protein [9]. In the present study, we used the synthetic
triterpenoid, CDDO-methyl amide (2-cyano-N-methyl-3,12-diox-
ooleana-1,9(11)-dien-28 amide; CDDO-MA) (Fig. 1A), which is at
least 200,000 times more potent than its naturally occurring
distant parent, oleanolic acid, as an inducer of NQO-1 or a
suppressor of iNOS [9,25]. The cytoprotective activity of these
triterpenoids is dependent on activation of Nrf2, since such activity
is lost, both in cell cultures and in vivo, in the absence of Nrf2
[9,26,28]. Furthermore, pharmacodynamically meaningful levels
of CDDO-MA are achievable in mouse brain after oral dosing, in
contrast to its immediate carboxylic acid parent, CDDO, which
has poor penetration of the blood-brain barrier.
In the present study, we found that CDDO-MA is a very potent
and selective activator of the neuroprotective Nrf2/ARE pathway.
Furthermore, due to its ability to activate the Nrf2 pathway,
CDDO-MA exerts profound neuroprotective effects against
MPTP and 3-NP neurotoxicity. We show that the neuroprotective
effects observed are due to its antioxidant effects, caused by
induction of pathways known to be regulated through Nrf2/ARE,
such as glutathione synthesis. This is the first report to show that a
synthetic oleanane triterpenoid can be neuroprotective in
experimental models of PD and HD, and has potential therapeutic
implications for the treatment of these disabling illnesses.
Results
CDDO-MA causes Nrf2 upregulation and nuclear
translocation to activate the ARE pathway
Previous studies have demonstrated that synthetic triterpenoids
activate Nrf2 mediated ARE transcription in non-neuronal
systems [9,26,28]. We studied the ability of CDDO-MA to
activate this pathway in a neuronal cell line. SH-SY5Y
neuroblastoma cells were treated with various doses of CDDO-
MA (0.5–2 mM) or DMSO as control and analyzed for cellular
localization of Nrf2 at different time points. After 8 hours of
CDDO-MA (1 mM) treatment Nrf2 from cytosol translocated to
nucleus as evidenced by its colocalization with the nuclear dye
DAPI while Nrf2 was retained in the cytosol in DMSO controls
(Figure 1B). Nuclear translocation of Nrf2 from cytosol was also
observed at 8 hours following CDDO-MA at doses of 0.5 and
2 mM (data not shown). Nuclear translocation of Nrf2 following
CDDO-MA (1 mM) treatment resulted in significant (0.5–4.5 fold)
increases in mRNA levels of Nrf2 and other ARE genes such as
NQO-1, glutathione reductase (GR) and hemeoxygenase-1 (HO-
1) as measured by RT-PCR at 8 and 24 hours compared to
DMSO controls (Fig. 1C). Increases in mRNA levels of Nrf2 and
ARE genes showed corresponding (0.5–4.8 fold) increase in levels
of their proteins at 24 hours after CDDO-MA treatment
determined by immunoblotting and densitometry analyses
(Fig. 1D and E). Protein levels of glutathione reductase were
markedly increased even at 8 hours of CDDO-MA treatment.
This upregulation of glutathione reductase mRNA and its protein
levels following CDDO-MA treatment resulted in a dose-
dependent increase in levels of reduced glutathione (GSH), a
non-significant decrease of oxidized glutathione (GSSG) and a
significant increase in the GSH/GSSG ratio measured in the total
cell lysate at 24 hours (Fig. 1F). The increase in GSH levels and
the ratio (GSH/GSSG) were dose-dependently increased with
doses of 0.5–2 mM CDDO-MA. These doses resulted in Nrf2
upregulation, its nuclear translocation, and activation of the ARE
pathway (Fig. 1F and data not shown).
CDDO-MA activates the ARE pathway in an Nrf2-
dependent manner and blocks t-butylhydroperoxide-
induced ROS generation
To determine if the activation of ARE pathway by CDDO-MA
is through the Nrf2-mediated transcription we studied mouse
embryonic fibroblasts from wild type and Nrf2 knockout mice
[30]. Following overnight treatment of CDDO-MA (100 nM) or
DMSO in wild type and Nrf2 knockout fibroblasts, analysis of
mRNA levels for the ARE genes such as glutathione S-transferase
alpha 3 (GSTa3), HO-1 and NQO-1 were studied using RT-PCR.
RT-PCR analyses of these ARE activated genes showed significant
5–6 fold inductions in wild type fibroblast cells, but not in the Nrf2
knockout cells (Fig. 2A). This suggests that indeed the ARE
activation caused by CDDO-MA is through Nrf2 mediated
transcription. Furthermore at a functional level we tested the
ability of CDDO-MA to block t-butylhydroperoxide generated
reactive oxygen species (ROS). Wild type and Nrf2 knockout
mouse embryonic fibroblasts were pre-treated overnight with
either CDDO-MA (1, 10, and 100 nM) or DMSO. The next day,
cells were loaded with a fluorescent indicator for 30 minutes and
then challenged with 250 uM t-butylhydroperoxide (a potent
oxidant known to generate toxic free radicals) for 15 minutes.
CDDO-MA treatment blocked t-butylhydroperoxide-induced
ROS generation in wild type fibroblast cells in a dose-dependent
manner, but there were no effects of CDDO-MA on t-
butylhydroperoxide-induced ROS generation in Nrf2 knockout
fibroblasts (Fig. 2B). CDDO-MA is, therefore, a potent and
selective activator of the Nrf2/ARE pathway and can scavenge t-
butylhydroperoxide-induced ROS generation through the induc-
tion of phase 2 detoxifying ARE genes only in the presence of
Nrf2.
Bioavailability of CDDO-MA in mouse brain
Due to its ability to activate the neuroprotective Nrf2/ARE
pathway in vitro we then administered CDDO-MA to mice in
order to test the neuroprotective efficacy of ARE activation in
animal models of neurodegeneration. CDDO-MA achieves
meaningful pharmacological levels in mouse brain in contrast to
the naturally occurring parent oleanolic acid when administered
by diet. The improved brain penetration of CDDO-MA was
achieved by chemical modification of the parent oleanolic acid by
replacing the carboxylic acid residue with the methyl amide group
Nrf2 and Neuroprotection
PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e5757Figure 1. CDDO-MA treatment to SH-SY5Y cells causes Nrf2 translocation to nucleus and subsequent activation of ARE pathway. A.
Chemical structures of oleanolic acid and CDDO-MA. Oleanolic acid is a naturally occurring triterpenoid with structural similarities to CDDO. CDDO
that is over 200,000 times more potent than the parent oleanolic acid was chemically modified by addition of a methyl group to obtain increased
brain bioavailability. B. SH-SY5Y neuroblastoma cells were treated with CDDO-MA (1 mM) or DMSO as a control. In DMSO controls Nrf2 is localized to
cytosol as immunostained by anti-Nrf2 antibody (closed arrow) with DAPI (open arrow) a nuclear stain. After 8 hours of CDDO-MA treatment Nrf2
from cytosol translocates to the nucleus and colocalizes with DAPI (straight arrow), Scale bar 12 mm. C. Nuclear translocation of Nrf2 results in a
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CDDO-MA in the diet (800 mg/kg of diet), mass spectrometry
analysis showed brain tissue levels ranging from 60–120 nM, a
level associated with marked induction of phase 2 enzymes and
suppression of iNOS and COX-2 in cell culture experiments
[9,25]. The dose we selected for these experiments (800 mg/kg of
diet) gave brain levels that were twice those found in mice fed only
400 mg/kg diet (Fig. 3).
CDDO-MA attenuates MPTP-induced nigrostriatal
dopaminergic neurodegeneration
We examined whether the ability of CDDO-MA to activate
Nrf2/ARE signaling is beneficial in an experimental animal model
of Parkinson’s disease. Mice were administered either CDDO-MA
(800 mg/kg of diet) or control rodent diet for 7 days before MPTP
(10 mg/kg, i.p. 3 doses every 2 hours in one day) and then for 7
days after MPTP. One week following the last MPTP treatment,
there was a profound reduction (about 80%) in total striatal
dopamine and also its metabolites 3,4-dihydroxyphenylacetic acid
(DOPAC), homovanillic acid (HVA) as compared to phosphate-
buffered saline (PBS) controls. CDDO-MA treatment significantly
attenuated MPTP-induced striatal depletion of dopamine and its
metabolites as compared to the MPTP group on control diet
(Table 1) (ANOVA, p,0.01). Immunohistochemical analysis of
dopaminergic neurons of the substantia nigra pars compacta
(SNpc) showed a profound loss of tyrosine hydroxylase (TH)-
immunoreactivity 7 days after acute MPTP as compared to PBS
controls. CDDO-MA treatment significantly protected against the
loss of TH-immunoreactive dopaminergic neurons in the SNpc
(Fig. 4A). Counts of total neurons (Nissl positive) and TH-
immunopositive neurons in the SNpc showed that treatment with
CDDO-MA significantly reduced the MPTP-induced loss of both
total and TH-immunopositive neurons (Fig. 4B) (ANOVA,
p,0.05).
We then studied CDDO-MA in a chronic paradigm of MPTP-
toxicity. The chronic MPTP model better mimics the neuropath-
ological features of PD in humans [31,32]. Mice were pre-treated
with either CDDO-MA or control diet. Seven days later animals
received a continuous infusion of MPTP (40 mg/kg/day for 28
days) or sodium phosphate-buffered saline (PBS) by subcutaneous
implantation of mini-osmotic pumps. Animals were administered
either CDDO-MA or control diet through out the duration of the
osmotic pumps. After 28 days, there was a significant reduction
(about 50%) in total striatal dopamine and also its metabolites,
Figure 2. Activation of Nrf2/ARE pathway by CDDO-MA is Nrf2 dependent. A. Wild type (WT) and Nrf2 knockout (KO) mouse embryonic
fibroblasts were pretreated with either CDDO-MA (1, 10 and 100 nM) or DMSO (as control) for 18 hours. Analysis of ARE genes showed a statistically
significant increase in GSTa3, HO-1 and NQO-1 in wild type fibroblasts compared to DMSO treated controls. Nrf2 knockout fibroblasts failed to induce
ARE genes following treatment with CDDO-MA compared to respective DMSO controls, implicating that CDDO-MA requires Nrf2 to activate ARE
signaling. Data represent mean6SEM, *P,0.001 when compared with the controls, by ANOVA, n=3 from two separate experiments. B. Wild type and
Nrf2 knockout mouse embryonic fibroblasts were pretreated with either CDDO-MA (1, 10 and 100 nM) or DMSO (as control) for 18 hours. The next
day, 250 mM tert-butyl hydroperoxide was added to these fibroblasts for 15 minutes, and generation of ROS was measured by flow cytometry. CDDO-
MA treatment resulted in a significant dose dependent reduction of tBHP-induced ROS generation in wild type fibroblasts. Nrf2 knockout fibroblasts
failed to show reduction in tBHP-induced ROS generation. *p,0.05 compared to knockout fibroblasts; #p,0.05 compared to 1 nM CDDO-MA, by
ANOVA, n=3 from two separate experiments.
doi:10.1371/journal.pone.0005757.g002
significant increase in mRNA levels of Nrf2 and other ARE genes such as NQO-1, glutathione reductase (GR) and HO-1 measured by RT-PCR at 8 and
24 hours after drug treatment. Data represented as Mean6SEM showing relative levels of mRNA at various time points compared to DMSO controls,
**p,0.05 and ***p,0.001. Students-t test, n=5 samples for each experimental groups. D and E. Increases in mRNA levels of Nrf2 and ARE genes
showed corresponding increases in levels of their respective proteins analyzed by western blotting and densitometry at 8 and 24 hours after CDDO-
MA treatment. Data represented as Mean6SEM showing relative percent change in levels of protein normalized to actin at various time points
compared to DMSO controls, **p,0.05 and ***p,0.001. Students-t test, n=6 samples for each experimental groups. F. CDDO-MA treatment resulted
in a significant dose-response increase in levels of reduced glutathione (GSH) measured at 24 hours. Data represented as Mean6SEM showing GSH
levels at 24 hours compared to DMSO controls, **p,0.05 and ***p,0.001 following Students t-test (n=6). Values represented as nanomoles/mg
protein from total cell lysate.
doi:10.1371/journal.pone.0005757.g001
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against MPTP-induced striatal depletion of dopamine and its
metabolites (Table 1) (ANOVA p,0.05). Immunohistochemical
analysis of the SNpc after 28 days showed a marked reduction of
total (Nissl positive) and TH-immunoreactive neurons following
MPTP. CDDO-MA treatment significantly protected against
MPTP-induced loss of TH-immunoreactive and total neurons of
the SNpc (Fig. 4C and D) (ANOVA, p,0.05).
The neuroprotective effects provided by CDDO-MA treatment
following MPTP-neurotoxicity were not due to impairment of the
metabolism of MPTP, since the striatal tissue levels of its
metabolite MPP
+ (1-methyl-4-phenyl-pyridinium ion) showed no
differences between the control (9.8560.69 ng/mg protein,
n=13) and the CDDO-MA treated mice (9.8360.50 ng/mg
protein, n=15), when measured after 28 days of chronic treatment
of MPTP (40 mg/kg/day for 28 days).
CDDO-MA blocks MPTP-induced lipid peroxidation and
a-synuclein accumulation
In order to determine if neuroprotective effects of CDDO-MA
can block MPTP-induced oxidative damage and increase in a-
synuclein accumulation we examined malondialdehyde and a-
synuclein immunostaining in SNpc. Chronic administration of
MPTP resulted in a marked induction of oxidative damage as
measured by malondialdehyde immunostaining (Fig. 4E), and
caused a marked increase in a-synuclein accumulation in SNpc
dopaminergic neurons (Fig. 4F). MPTP-induced a-synuclein
accumulation was observed in TH-positive neurons of SNpc as
determined by colocalization of a-synuclein- and TH-immuno-
staining employing confocal microscopy (data not shown).
Treatment with CDDO-MA blocked MPTP-induced mesence-
phalic malondialdehyde formation and accumulation of a-
synuclein (Fig. 4E and F). These data show that CDDO-MA
produces neuroprotective effects by reducing oxidative stress. It
also reduces a-synuclein accumulation in the SNpc.
CDDO-MA blocks 3-nitropropionic acid-induced striatal
toxicity
3-Nitropropionic acid (3-NP) administration in rodents is known
to cause striatal degeneration known to replicate pathological
features of Huntington’s disease [33]. Lewis rats were pretreated
either with CDDO-MA (800 mg/kg of diet) or control diet for one
week. 3-NP (50 mg/kg/day for 7 days) or PBS was delivered
chronically by subcutaneous implantation of mini-osmotic pumps.
Animals were treated with either CDDO-MA or control diet
throughout the administration of 3-NP. Analysis of striatal neurons
by neuron-specific nuclear protein (NeuN) immunohistochemistry
after 3-NP administration showed a profound loss of striatal
neurons. CDDO-MA treatment significantly attenuated 3-NP-
induced loss of striatal NeuN stained neurons (Fig 5A). Quanti-
tative assessment showed that 3-NP induced striatal lesion volumes
were reduced by more than 70% by administration of CDDO-MA
(Fig. 5B) (p,0.01).
CDDO-MA preserves 3-NP-induced impairment of striatal
glutathione homeostasis, and blocks oxidative damages
Striatal degeneration caused by 3-NP administration in rodents
induces oxidative damage, especially alterations in glutathione
homeostasis [34]. We pretreated rats either with CDDO-MA
Figure 3. Brain bioavailability of CDDO-MA in mice. CDDO-MA
shows pharmacodynamically meaningful levels in brain. A dose-
dependent increase in concentration of CDDO-MA was observed using
an LC-MS analysis of acetonitrile brain extracts measured following
administration CDDO-MA (at 200, 400 and 800 mg/kg of rodent diet) for
one week, n=5 mice per group. Vehicle diet consisting of 1:3
(ethanol:Neobee oil) showed no CDDO-MA levels in brain (data not
shown).
doi:10.1371/journal.pone.0005757.g003
Table 1. Neuroprotective effects of CDDO-MA on striatal dopamine and its metabolites in MPTP neurotoxicity.
Animal (n) Dopamine DOPAC HVA
Acute MPTP model
Control+PBS 5 90.1061.7 7.0460.2 12.4760.6
CDDO-MA+PBS 5 85.3563.6 7.0660.3 11.5860.7
Control+MPTP 10 17.8661.1## 2.1760.1## 5.2060.1##
CDDO-MA+MPTP 10 46.2266.3## ** 4.2860.4## ** 8.2660.5## **
Chronic MPTP model
Control+PBS 5 87.7362.6 8.0060.2 9.7860.4
CDDO-MA+PBS 5 86.9963.5 7.8860.3 9.2060.3
Control+MPTP 13 41.6064.6## 1.5760.1## 4.0560.2##
CDDO-MA+MPTP 15 60.0764.7# * 2.3260.3# * 5.1060.2# *
aData are expressed as mean6SEM. Values represent as ng per mg protein.
b#,p ,0.05, ##,p ,0.01compared to PBS groups; *, p,0.05, **, p,0.01 compared to control diet +MPTP group, ANOVA, Student-Newman-Keul’s post test.
doi:10.1371/journal.pone.0005757.t001
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PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e5757Figure 4. CDDO-MA attenuates MPTP-induced nigrostriatal dopaminergic neurodegeneration. Mice were pre-treated with either CDDO-
MA or control diet 7 days before acute (MPTP 10 mg/kg, i.p. 3 doses every 2 hours in one day) and chronic (MPTP 40 mg/kg, for 28 day through
continuous subcutaneous infusion using mini-osmotic pumps) MPTP treatment. Control animals received identical volumes of PBS. A
Photomicrographs of TH-immunostained sections through the SNpc of mice on acute MPTP show a significant reduction in TH-positive neurons
of SNpc. CDDO-MA treatment significantly blocked MPTP-induced loss of TH-positive neurons. B. Consistent with TH-immunostaining of SNpc,
Nrf2 and Neuroprotection
PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e5757Figure 5. CDDO-MA reduces striatal damage caused by 3-NP toxicity, and blocks 3-NP induced striatal glutathione depletion. Lewis
rats were pre-treated with either CDDO-MA diet (800 mg/kg) or control diet 7 days followed by continuous infusion of 3-NP (50 mg/kg/day) delivered
through subcutaneously implanted miniosmotic pumps for 7 days. A. Photomicrographs of NeuN-immunostained sections through the coronal
section of striatum and cortex of rats treated with control diet+PBS (left), control diet with 3-NP (middle) and CDDO-MA diet with 3-NP (right) show a
significant loss of NeuN positive cells in 3-NP treated cortex and caudate compared to PBS controls. CDDO-MA treatment significantly reduced 3-NP
induced loss of cortical and caudate NeuN positive cells. High magnifications in lower panel show the striatal neuronal loss caused by 3-NP and
preservation by CDDO-MA. B. Consistent with loss of NeuN positive cells in cortex and the caudate, measurement of lesion volume in coronal brain
slices of 3-NP treated controls show a significant increase in striatal lesion volumes. The administration of CDDO-MA significantly reduces striatal
lesion volumes caused by 3-NP. Data represent mean6SEM. *p,0.01, statistical significance compared to 3-NP treated controls, by student-t test,
n=15 rats per group. C. Rats described above were also used for analysis of striatal levels of reduced and oxidized glutathione. 3-NP administration
resulted in a statistically significant reduction of striatal levels of reduced glutathione (GSH) and the ratio of reduced and oxidized glutathione (GSH/
GSSG), whereas levels of oxidized glutathione (GSSG) were not significantly affected by 3-NP treatment measured by HPLC-electrochemistry. CDDO-
MA treatment significantly blocked 3-NP induced reductions in striatal levels of GSH and the ratio of GSH/GSSG without impacting the GSSG levels.
Data represent mean6SEM. *p,0.05, statistical significance compared to controls and
#p,0.05 compared to 3-NP treatment, by ANOVA, n=10 rats
per group.
doi:10.1371/journal.pone.0005757.g005
stereologic cell counts of total (Nissl-positive) and TH-immunopositive neurons of SNpc showed a significant loss following MPTP administration
which was significantly attenuated by CDDO-MA treatment. C. Photomicrographs of TH-immunostained sections through the SNpc of mice on
chronic MPTP show a significant reduction in TH-positive neurons of SNpc. CDDO-MA treatment significantly blocked MPTP-induced loss of TH-
positive neurons. D. Consistent with TH-immunostaining of SNpc, stereologic cell counts of total (Nissl-positive) and TH-immunopositive neurons of
SNpc showed a significant loss following MPTP administration which was significantly attenuated by CDDO-MA treatment. n=10 mice per group.
#p,0.05 compared to control diet alone; *P,0.05 when compared with the control diets with MPTP group. E. Photomicrographs of malondialdehyde
(MDA)-immunostained sections through the SNpc of mice on chronic MPTP show a significant increase of MDA staining in SNpc of MPTP treated
animals. CDDO-MA treatment resulted in a marked reduction of MPTP-induced MDA formation. Representative image from n=5 mice in each group.
F. Photomicrographs of a-synuclein stained sections through the SNpc of mice on chronic MPTP show a significant increase of a-synuclein
accumulation in SNpc of MPTP treated animals. CDDO-MA treatment resulted in a significant reduction of MPTP-induced a-synuclein accumulation in
SNpc neurons. High magnification inserts show the a-synuclein staining in neurons. Representative image from n=5 mice in each group.
doi:10.1371/journal.pone.0005757.g004
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osmotic pump delivery of 3-NP (50 mg/kg/day for 7 days).
Administration of 3-NP resulted in a significant reduction of
reduced glutathione (GSH), and the ratio of reduced to oxidized
glutathione (GSH/GSSG). Treatment with CDDO-MA signifi-
cantly blocked 3-NP-induced depletion of striatal GSH and the
ratio of GSH/GSSG (Fig. 5C).
Immunohistochemical analysis of striatal slices after 3-NP
showed a marked increase in malondialdehyde staining. CDDO-
MA treatment completely blocked 3-NP induced malondialdehyde
staining in the striatum (Fig. 6A). Quantitative measurement of
malondialdehyde by high-performance liquid chromatography
(HPLC) revealed a significant increase of malondialdehyde both in
striatum and cerebral cortex following 3-NP treatment. 3-NP
induced elevations of malondialdehyde levels in these two areas
were significantly attenuated by CDDO-MA treatment (Fig. 6B).
F2-Isoprostanes, a marker of lipid peroxidation, showed a marked
increase after 3-NP treatment. CDDO-MA significantly blocked
3-NP induced generation of F2-Isoprostanes (Fig. 6C). Further-
more, administration of 3-NP resulted in DNA oxidation as
measured by the ratio of 8-hydroxy-2-deoxyguanosine
(8OH2dG)/deoxyguanosine (dG) in the cerebral cortex, which
was significantly attenuated by CDDO-MA administration
(Fig. 6D). 3-NP administration produced a profound increase in
striatal immunostaining of 3-nitrotyrosine, a nitrated tyrosine
marker for protein oxidation, which was markedly attenuated by
treatment with CDDO-MA (Fig. 6E). These results suggest that
CDDO-MA blocks oxidative damage seen in 3-NP model in rats.
Overall, our results show that CDDO-MA is a selective and
potent activator of the Nrf2/ARE signaling pathway and
Figure 6. CDDO-MA treatment blocks 3-NP induced oxidative damage. Lewis rats described in figure 4 were also used for striatal and
cortical levels of oxidative damage markers. A. Photomicrographs of malondialdehyde (MDA)-immunostained coronal sections of the striatum of rats
administered with 3-NP shows an increase in MDA staining in striatum. Treatment with CDDO-MA markedly reduced 3-NP induced MDA
immunostaining in the striatum, n=5 mice per group, scale bar: 100 mm B. Consistent with the striatal immunostaining of MDA, HPLC-
electrochemical analysis of MDA levels in striatum and cortex show 3-NP resulted in a statistically significant increase in MDA levels. CDDO-MA
treatment significantly reduced 3-NP induced MDA formation in striatum and cortex. Data represent mean6SEM. *p,0.05 compared to normal
controls and
#p,0.05 compared to 3-NP treatment, by ANOVA, n=10 rats per group. C. Gas chromatography/Mass spectrometric analysis of
esterified F2-Isoprostanes (F2-IsoPs) in cerebral cortex from rats treated with 3-NP showed significant increases in F2-IsoPs levels. CDDO-MA treatment
significantly abrogated 3-NP induced cortical increases in F2-IsoPs levels. Data represent mean6SEM. *p,0.05 compared to normal controls and
#p,0.05 compared to 3-NP treatment, by ANOVA, n=10 rats per group. D. HPLC-electrochemical analysis of the ratio of 8OH2dG over dG shows a
significant increase in oxidative DNA damage in the cerebral cortex following 3-NP treatment which is significantly attenuated due to CDDO-MA
administration. Data represent mean6SEM. *p,0.05 compared to normal controls and
#p,0.05 compared to 3-NP treatment, by ANOVA, n=10 rats
per group. E. Photomicrographs of 3-nitrotyrosine-immunostained coronal brain sections through the striatum of rats show a significant elevation in
3-nitrotyrosine levels (a marker of protein nitration) due to 3-NP administration. Treatment of CDDO-MA significantly reduced 3-NP induced increase
in immunostaining of striatal 3-nitrotyrosine, n=5 rats per group, scale bar: 100 mm.
doi:10.1371/journal.pone.0005757.g006
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Discussion
A promising pathway for neurotherapeutics in neurodegener-
ative diseases is the Nrf2/ARE signaling pathway [3–5]. The
ability to induce neuroprotective phase 2 detoxifying genes, as well
as antioxidant enzymes at transcriptional level, could have
significant advantages over more conventional approaches. One
can potentially induce an ongoing neuroprotective response which
would not be dependent on the antioxidant effects of single
molecules, which are frequently consumed while scavenging
reactive oxygen species (ROS).
Under basal conditions, Nrf2 is anchored in the cytoplasm to
the actin bound protein KEAP1. In response to oxidative stress
Nrf2 is released from the KEAP1/Nrf2 complex and then
activates ARE-mediated gene transcription [7,8,10]. Genes known
to have ARE response elements include glutathione-S-transferases,
NQO-1, HO-1, thioredoxin, and enzymes involved in glutathione
synthesis. A number of other genes are also under the regulatory
control of Nrf2/ARE signaling which are involved in immune
function and inflammation [3]. Furthermore, a number of growth
factors including nerve growth factor, fibroblast growth factor, and
brain derived neurotrophic factor are induced in primary neurons
by activation of the Nrf2/ARE pathway [3,13]. Additionally, a
number of enzymes involved in glycolytic metabolism, as well as
heat shock proteins, and ferritin light and heavy chains are also
induced. Of particular interest are iNOS and COX-2 which are
downregulated due to activation of Nrf2 signaling. These pro-
inflammatory genes have been implicated in inflammatory
pathways involved in a number of neurodegenerative diseases
including PD, Alzheimer’s disease and amyotrophic lateral
sclerosis [17,35–38].
Thus pharmacological agents that have the ability to activate
the Nrf2/ARE signaling pathway hold great promise for
therapeutic intervention in neurodegenerative diseases. One such
class of compounds known to activate this pathway is the
triterpenoids [12]. Triterpenoids are synthesized by the cyclization
of squalene, a triterpene hydrocarbon found ubiquitously in nature
including plants and humans. More than 20,000 triterpenoids are
known to occur in nature of which oleanolic acid has been used for
centuries in traditional Asian medicine, due to its anti-inflamma-
tory activity. Using an assay for iNOS, a derivative of oleanolic
acid CDDO (2-cyano-3, 12-dioxooleana-1,9-dien-28-oic acid) was
identified that is over 200,000 times more active than its parent
molecule oleanolic acid [12]. Structure-activity analysis shows that
a, b-unsaturated carbonyl groups in CDDO at key positions on
rings A and C are essential for enabling Michael addition with a
nucleophilic target similar to Keap 1 (a protein with multiple
nucleophilic –SH residues and a cytoplasmic repressor of Nrf2).
This reaction activates the phase 2 responses, an intrinsic
mechanism used by cells to deactivate electrophiles or oxidative
stress [12]. In the present study, human neuroblastoma cells
treated by CDDO-MA demonstrated a stream of changes in the
phase 2 response through Nrf2/ARE pathway activation. These
include induction of Nrf2 protein levels and subsequent nuclear
translocation from the cytosol. The nuclear translocation of Nrf2
resulted in induction of phase 2 genes encoding a coordinated
family of cytoprotective proteins that include the enzymes of
glutathione synthesis and transfer, the quinone oxidoreductase
NQO-1, and the hemeoxygenase HO-1. Significantly, the phase 2
response in neuroblastoma cells due to CDDO-MA was translated
functionally by a dose dependent increase in cellular GSH
production, one of the major cellular antioxidants under the
regulatory control of Nrf2/ARE signaling [20]. Another signifi-
cant finding in our study is that the phase 2 response due to Nrf2/
ARE activation by CDDO-MA is selective and depends on the
presence of a functional Nrf2. In mouse embryonic fibroblast cells
derived from wild type mice CDDO-MA treatment resulted in
induction of mRNA levels for ARE genes such as GSTa3, NQO-1
and HO-1. The induction of these ARE genes was completely
absent in embryonic fibroblasts cells from Nrf2 knockout mice.
This effect was consistent with the dose-dependent reduction of t-
butylhydroperoxide-induced ROS in wild type but not Nrf2
knockout fibroblast cells. It is thus plausible that CDDO-MA may
very well enable Michael’s addition to its target Keap1 which is the
cytosolic repressor of Nrf2, since induction of ARE genes require
presence of functional Nrf2 and its translocation from cytosol to
nucleus. Previously, the ability of synthetic triterpenoids to activate
the ARE pathway in other model systems was demonstrated
[9,26,28]. However, our results in the present study for the first
time have shown that synthetic triterpenoids such as CDDO-MA
are potent inducers of Nrf2 expression, and activators of the ARE
pathway in a neuronal cell line.
Previous in vitro studies showed that neuronal cultures derived
from Nrf2 knockout mice have increased susceptibility to oxidative
stress, as well as damage produced by mitochondrial electron
transport chain complex inhibitors such as rotenone, MPP
+, 3-NP
and malonate [19]. Furthermore, Nrf2 deficient mice show
profound susceptibility to striatal lesions produced by the
mitochondrial complex 2 inhibitor malonate [21]. Conversely,
the implantation of intrastriatal grafts of astrocytes overexpressing
Nrf2, produced neuroprotection against the neurotoxic effects of
malonate. Recently, transgenic mice overexpressing Nrf2 in
astrocytes were shown to be resistant to MPTP toxicity and to
extend survival when crossed with a transgenic mouse mode of
ALS [22,23]. In order to study the neuroprotective efficacy of
CDDO-MA induced activation of Nrf2/ARE pathway in vivo we
used two neurotoxic paradigms of MPTP, involving acute 7-day
and chronic continuous infusion for four weeks in mice.
Administration of CDDO-MA produced significant neuroprotec-
tion against loss of striatal dopamine and its metabolites.
Furthermore, it produced significant protection against loss of
tyrosine hydroxylase immunoreactive neurons in the SNpc. These
data are consistent with MPTP-induced enhanced susceptibility to
nigrostriatal dopaminergic neurodegeneration in Nrf2 knockout
mice, suggesting that impairment of Nrf2/ARE signaling is an
important mediator of dopaminergic neurodegeneration [39].
Additionally, in the chronic MPTP neurotoxicity paradigm, there
was increased accumulation of a-synuclein (a neuropathological
feature seen in PD) in dopaminergic neurons, which was blocked
by administration of CDDO-MA. This is consistent with other
reports where chronic administration of MPTP, and other toxins
which specifically target mitochondria such as rotenone and
paraquat, produce mitochondrial dysfunction leading to oxidative
stress resulting in a-synuclein accumulation in SNpc neurons
[31,32,40,41]. Interestingly, mice lacking a-synuclein are resistant
to mitochondrial toxins [31,42] whereas human A53T a-
synuclein-overexpressing mice are known to develop neuronal
mitochondrial degeneration and cell death through induction of
oxidative stress [43,44]. This notion gains support from a recent
study where activation of phase 2 detoxification enzymes blocked
oxidative stress induced dopaminergic neurodegeneration in a a-
synuclein fly model [45]. Notably, in our studies chronic MPTP-
induced oxidative damage in SNpc neurons as measured by
malondialdehyde staining was markedly blocked by CDDO-MA
administration. This effect of CDDO-MA is consistent with its
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butylhydroperoxide induced ROS generation.
Previous reports have demonstrated that Nrf2 knockout mice
are more sensitive to 3-NP toxicity [20]. In cultured astrocytes, 3-
NP increases Nrf2 activity, which may account for the increased
sensitivity of Nrf2 deficient animals to 3-NP toxicity in vivo [20].
Additionally, dietary supplementation with the Nrf2 inducer
tertbutylhydroquinone attenuated 3-NP toxicity in Nrf2 compe-
tent mice, but not in Nrf2 deficient mice [20]. To further
demonstrate that activation of Nrf2/ARE pathway by CDDO-
MA could be beneficial in a rodent model of 3-NP mediated HD,
we employed systemic administration of 3-NP toxicity in Lewis
rats [46]. Our findings demonstrate that administration of
CDDO-MA reduced the striatal lesion volumes by more than
70%. Histological evaluation confirmed that CDDO-MA signif-
icantly protects against 3-NP induced neuronal death. Addition-
ally, we observed that CDDO-MA blocked 3-NP induced
increases in 8-hydroxy-2-deoxyguanosine, a marker of oxidative
damage to DNA, and malondialdehyde levels in the striatum and
cortex. Increases in F2-Isoprostanes (F2-IsoPs) in cerebral cortex
produced by 3-NP were blocked by CDDO-MA. F2-Isoprostanes
are prostaglandin-like lipids derived from the free-radical medi-
ated peroxidation of arachidonic acid [47,48]. The measurement
of F2-IsoPs by GC/MS is considered the most accurate index of
lipid peroxidation in vivo, and elevated levels of tissue-esterified and
free F2-IsoPs have been described in numerous neurodegenerative
diseases [48], including Huntington’s disease [49].
Increases in 3-NP induced immunostaining for malondialde-
hyde and 3-nitrotyrosine, a marker of protein nitration, were
blocked by CDDO-MA administration. Furthermore, increased
production of glutathione, due to induction of glutathione
synthetic enzymes is a well known effect of increased expression
of the Nrf2/ARE genes. We found that administration of 3-NP
significantly reduced striatal concentrations of reduced glutathione
(GSH), and the reduction in GSH and the ratio of GSH/GSSG
were completely prevented by CDDO-MA administration. This is
consistent with adenoviral overexpression of Nrf2 in the striatum,
which mainly infects astrocytes, which was sufficient to reduce 3-
NP toxicity in vivo by synthesis of GSH [20]. This view is further
strengthened when only a small number of Nrf2 expressing
astrocytes can confer neuroprotection to many neighboring
neurons during an oxidative glutamate insult in vitro [3,21,50].
These Nrf2 overexpressing astrocytes secrete high levels of
glutathione, providing a means for a small number of astrocytes
to affect the survival of a much larger number of neurons. Similar
observations were made in transgenic mice overexpressing Nrf2 in
astrocytes. When these mice were crossed with two transgenic
mouse models of familial amyotrophic lateral sclerosis, they
delayed onset and extended survival [23]. Motor neuron
protection was dependent on glutathione secretion in vitro and
spinal cord glutathione levels were increased in vivo. Our results
demonstrating a dose-dependent increase of cellular GSH levels in
neuroblastoma cells following CDDO-MA treatment, also suggests
that CDDO-MA not only impacts glutathione synthesis in
astrocytes in vivo, but also may activate inherent neuronal GSH
synthesis to provide neuroprotection against 3-NP neurotoxicity.
In summary the present study demonstrates that CDDO-MA is
a potent activator of Nrf2/ARE signaling pathway and renders
neuroprotection against MPTP and 3-NP neurotoxicity. We
recently showed that CDDO-MA reduces b-amyloid deposition
and improves memory in a transgenic mouse model of Alzheimer’s
disease [51]. In that study we showed that administration of
CDDO-MA increased brain levels of HO-1, an Nrf2/ARE
dependent enzyme. These results provide compelling evidence
for the utility of pharmacological agents known to activate Nrf2/
ARE mediated phase 2 detoxification genes for the treatment of
neurodegenerative diseases. Currently the parent compound,
CDDO, and its close relative, CDDO-methyl ester, are in Phase
I studies for the treatment of cancer. For applications in
neurodegenerative disease, the superior pharmacokinetics of
CDDO-MA in the brain provides a rationale for further
investigation of this agent, as well as related triterpenoid amides.
Our data provide a strong rationale for further preclinical
investigation of CDDO-MA and other related amides, directed
toward eventual clinical trials in patients with Parkinson’s and
Huntington’s disease.
Materials and Methods
Cell Culture studies
Human neuroblastoma SH-SY5Y cells (ATCC, Manassas, VA)
were cultured in DMEM supplemented with 10% FBS, 100 U/ml
penicillin, and 100 mg/ml streptomycin at 37uC in a humidified
atmosphere of 5% CO2. Cells were cultured up to 80–90%
confluency in 10 cm dishes for real time PCR, western blotting
and measurement of GSH and GSSG. For western blot analysis
cells were harvested in lysis buffer (50 mm Tris–HCl, pH 7.4,
150 mm NaCl, 5 mm EDTA, 1% sodium dodecyl sulfate (SDS))
supplemented with the protease inhibitor cocktail (EDTA-free,
Roche) and a phosphatase inhibitor cocktail (Sigma). Ten mgo f
the total protein were subjected to immunoblot analyses by a
described method [32] using appropriate primary antibodies (anti-
Nrf2, (1:1000 Epitomics CA); anti-NQO1, anti-glutathione
reductase and anti-heme oxygenase-1 (1:1000 Abcam MA) and
anti-b-actin Chemicon 1:10,000)). Densitometric analyses were
performed using the NIH Image J Software.
Nrf2 immunostaining was performed in SH-SY5Y cells cultured
at a density of 1610
26 cells/ml in 4 well chamber slides (BD
Biosciences CA). Cells were fixed at room temperature with 2%
paraformaldehyde in phosphate buffered saline (PBS), washed
three times in PBS for 5 min, and permeabilized with 0.1%
TritonX-100 in PBS. Non-specific antibody binding was blocked
with 5% normal goat serum (NGS) in PBS for 1 h at room
temperature. Then, cells were incubated overnight at 4uC with
rabbit monoclonal anti-Nrf2 antibody (1:200 in PBS plus 1.5%
NGS, Epitomics CA), washed three times with PBS, and further
incubated with Cy3-conjugated anti-rabbit IgG (1:500 in PBS plus
0.1% NGS, Jackson Immunoresearch, PA) for 2 h at room
temperature. They were washed in PBS three times for 5 minutes
each at room temperature and incubated with 49,6-diamidino-2-
phenylindole, dilactate (DAPI, dilactate) (1:1000, Invitrogen,
Carlsbad, CA) for 10 minutes and rinsed in distilled water, air
dried and cover slipped using immumount mounting media
(Thermo Shandon, Pittsburg, PA). For microscopic analysis, the
sections were visualized using a Zeiss Confocal microscope (LSM
510 Meta) (Carl Zeiss Vision, Hallbergmoos, Germany) equipped
with an argon laser. DAPI immunofluorescence was given a
pseudo green color in order to demonstrate a clear contrast for
Nrf2 co-localization with nuclear stain DAPI following CDDO-
MA treatment.
RNA isolation and real-time RT-PCR
Total RNA from SH-SY5Y and mouse embryonic fibroblast
cells were isolated according to manufacturer’s protocol using
TRIzol reagent (Invitrogen CA). Total RNA purity and integrity
was confirmed by ND-1000 NanoDrop (NanoDrop Technologies)
and 2100 Bioanalyzer (Agilent). Real-time PCR was performed
using the ABI prism 7900 HT sequence detection system (Applied
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for various genes indicated and housekeeping gene GAPDH.
Relative expression was calculated using the DD Ct method [53].
Measurement of reactive oxygen species in mouse
embryonic fibroblasts
Wild type and Nrf2 knockout mouse embryonic fibroblasts were
treated with CDDO-MA for 18 hours and incubated with
10 mmol/L nonfluorescent indicator H2DCFDA (29,7 9-Dichlor-
odihydrofluorescein diacetate, Invitrogen CA) for 30 minutes.
Cells were challenged with 250 mmol/L tert-butyl hydroperoxide
(tBHP) for 15 minutes, and mean fluorescence intensity of 10,000
cells was analyzed by FACScan flow cytometry (Becton Dickinson,
NJ) using a 480-nm excitation wavelength and a 525-nm emission
wavelength.
Animals and materials
Male C57BL/6 mice (3-month old, 25–30 g) and male Lewis
rats (3-month old, 250–300 g) were obtained from the Jackson
Laboratory (Bar Harbor, ME, USA). Neurotoxins MPTP and
3NP, neurochemicals dopamine, DOPAC and HVA, and
malondialdehyde (MDA) were all purchased from Sigma (St.
Louis, MO, USA). CDDO-MA was synthesized by the conden-
sation of methyl amide with CDDO acid chloride [25]. This stable
derivative was blended into powdered rodent chow (Lab Diets
5002), after being dissolved in a vehicle comprising of 1 part
ethanol/3 parts Neobee Oil (coconut oil triglyceride). For each kg
of diet, 800 mg of CDDO-MA was dissolved in 50 ml of the above
vehicle before mixing with the chow; the resulting diet was then
pelleted for feeding. CDDO-MA is stable (by mass spec analysis) in
this feed. All animal experimental procedures were in strict
accordance with protocols approved by the Weill Cornell Medical
College Institutional Animal Care and Use Committee (IACUC).
MPTP and 3-NP manipulations were carried out in a special
animal room restricted for neurotoxin manipulation.
MPTP neurotoxicity paradigms and CDDO-MA
treatments
C57BL/6 mice were fed with CDDO-MA-containing or control
diet for one week before MPTP injection [54]. MPTP-HCl
dissolved in PBS was injected intraperitoneally 10 mg/kg, free
base for 3 times with an interval of 2 hours. Diets were continued
for 7 days after the MPTP injection till they were sacrificed for
toxicity analyses. Another group of C57BL/6 mice fed with
CDDO-MA-containing or control diet for one week were
implanted subcutaneously with osmotic minipumps (Model 2004,
Alzet, Cupertino CA, filled with MPTP 170 mg/ml in PBS) that
delivered MPTP at a dose of 40 mg/kg body weight daily for 28
day. They were maintained on the same diets. Then mice were
sacrificed and tissues were prepared as above except that a piece of
striatum from each mouse was saved for MPP
+ level measure-
ments.
Rat model of 3-NP toxicity
Male Lewis rats fed with CDDO-MA-containing or control diet
for 7 days were implanted subcutaneously with osmotic mini-
pumps (Model 2ML1, Alzet, Cupertino CA, filled with 3-NP
54 mg/ml in PBS, pH 7.4) that delivered 3-NP 50 mg per kg
bodyweight daily for 7 days while remaining on the same diets
[46]. Then rats were sacrificed and one half of the brain was fixed
in 4% paraformaldehyde for the striatal lesion volume measure-
ment and the other half was dissected freshly for GSH, GSSG, F2-
Isoprostanes (F2-IsoPs) and MDA assays.
HPLC analysis for catecholamines and MPP
+
Striatal levels of dopamine and its metabolites DOPAC and
HVA were measured after sonication and centrifugation in chilled
0.1 M perchloric acid (PCA, about 100 ul/mg tissue) as modified
from our previously described method [55]. Briefly, 15 ul
supernatant was isocratically eluted through an 8064.6 mm C18
column (ESA, Inc Chelmsford, MA) with a mobile phase
containing 0.1 M LiH2PO4, 0.85 mM 1-octanesulfonic acid and
10% (v/v) methanol and detected by a 2-channel Coulochem II
electrochemical detector (ESA, Inc. Chelmsford, MA). Concen-
trations of dopamine, DOPAC and HVA are expressed as ng per
mg protein. The protein concentrations of tissue homogenates
were measured according to the Bio-Rad protein analysis protocol
(Bio-Rad Laboratories, Hercules, CA) and Perkin Elmer Bio Assay
Reader (Norwalk, CT). MPP
+ was measured according to
described method [56].
HPLC analysis for malondialdehyde
The determination of malondialdehyde by HPLC was carried
out according to a reported method [57]. Briefly, tissues were
homogenized in 40% ethanol solution. To a 50-ml aliquot of
sample or MDA standard, 50 ml of 0.05% butylated hydroxyto-
luene (BHT), 400 ml of 0.44 M H3PO4, and 100 ml of 0.42 mM 2-
thiobarbituric acid (TBA) were added and heated for 1 h on a
100uC, followed by 250 ml n-butanol extraction of the MDA–TBA
derivative. The HPLC mobile phase comprised of acetonitrile–
buffer (20:80, v/v, buffer 50 mM KH2PO4, pH of 6.8 adjusted
with KOH). The column was an ESA 15063-mm C18 column
with particle size of 3 mm (ESA, Inc.). The fluorescence detector
was set at an excitation wavelength of 515 nm and emission
wavelength of 553 nm. The concentration of MDA is expressed as
nmol per mg protein.
GC/MS analysis for F2-Isoprostanes
Membrane-esterified F2-Isoprostanes (F2-IsoPs) were measured
by stable isotope dilution, negative-ion chemical ionization gas
chromatography/mass spectrometry using a
4H2-8-iso PGF2a
internal standard as previously described [47]. Briefly, brain tissue
samples were homogenized in 2:1 chloroform:methanol contain-
ing 0.5% butylated hydroxytolulene and lipids were extracted by
the method of Folch [58]. Esterified F2-IsoPs were hydrolyzed by
chemical saponification with 15% potassium hydroxide, extracted
using C18 and silica Sep-Pak cartridges (Waters Corporation,
Milford, MA), purified by thin-layer chromatography, converted
to pentafluorobenzyl ester trimethylsilyl ether derivates, and
quantified using gas chromatography/negative ion chemical
ionization/mass spectrometry. Quantification of F2-IsoPs was
performed by comparison to a known amount of
4H2-8-iso PGF2a
internal standard.
HPLC analysis for 8OH2dG and dG
DNA extraction and HPLC analysis methods were modified
from a previous report [59]. Briefly, rat cortex DNA was extracted
using TRIzol reagent (Invitrogen, CA, USA) with the inclusion of
1 mM deferoxamine mesylate (DFOM). DNA pellets in 80 ul of
H2O were hydrolyzed by adding 10 ml of Nuclease P1 (0.4 U/ml
in 300 mM sodium acetate, 0.2 mM ZnCl2, pH 5.3), and 5 mlo f
alkaline phosphatase (1 U/ml). The hydrolysate (100 ml) was
mixed with 2 ml of 5 M perchloric acid and centrifuged at
18,000 g for enzyme removal. The supernatant (50 ml) was
isocratically eluted through a 4.66250 mm C18 column (ESA,
Inc Chelmsford, MA) with a mobile phase containing 20 mM
LiH2PO4, 4.0 mM 1-octanesulfonic acid and 1% (v/v) methanol
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detector (ESA, Inc. Chelmsford, MA), set with potentials of
Channel 1 at 165 mV and Channel 2 at 300 mV for 8OH2dG,
and followed by a Waters 486 UV detactor set with a wavelength
at 260 nm for dG. DNA oxidation was indicated by the
concentration ratio of 8OH2dG 610
3 vs. dG.
HPLC analysis for GSH and GSSG
Brain tissues were homogenized while SH-SY5Y cells were
sonicated in chilled 0.1 M perchloric acid and centrifuged. The
supernatants were taken for HPLC as modified from a reported
method [60]. Breifly, 15 ul supernatant was isocratically eluted
through a 4.66150 mm C18 column (ESA, Inc Chelmsford, MA)
with a mobile phase containing 50 mM LiH2PO4, 1.0 mM 1-
octanesulfonic acid and 1.5% (v/v) methanol and detected by a 2-
channel Coulochem III electrochemical detector (ESA, Inc.
Chelmsford, MA), set with guard cell potential 950 mV, Channel
1 potential 500 mM for GSH detection and Channel 2 potential
880 mV for GSSG detection. Concentrations of GSH and GSSG
are expressed as nmol per mg protein.
Immunohistochemistry and stereologic analysis
Tissues for histological analysis were fixed with 4% parafor-
maldehyde in 0.1 M phosphate buffer (pH 7.4) and then
cryoprotected in 30% sucrose overnight at 4uC. A modified
avidin-biotin-peroxidase technique was employed for immunohis-
tochemistry. Briefly, 35 micrometer thick coronal brain sections
were pretreated with 3% H2O2 in 0.1 M PBS for 30 min. The
sections were rinsed in PBS twice for 5 min each. The sections
were incubated sequentially in (a) 1% bovine serum albumin
(BSA)/0.2% Triton X-100 (Sigma, St. Louis, MO) for 30 minutes,
(b) appropriate primary antibodies (rabbit anti-TH affinity purified
antibody (1:4,000; Chemicon, Temecula, CA), rabbit immunoaf-
finity purified anti-nitrotyrosine (4 mg/ml; Upstate Biotechnology,
Lake Placid, NY), rabbit polyclonal anti-malondialdehyde
(1:1,000; provided by Dr. C. Thomas, Hoechst Marion Roussel),
mouse anti-a-synuclein (1:1,000; BD Transduction Laboratories,
San Jose, CA), mouse anti-NeuN (1:1,000; Chemicon, Temecula,
CA)) (diluted in PBS/0.5% BSA) for 18 hours, (c) appropriate
biotinylated IgG (1:200, diluted in PBS/0.5% BSA, Vector
Laboratories, Burlingame, CA) for 1 hour, and (d) avidin-biotin-
peroxidase complex (1:200 in PBS; Vector Laboratories) for
1 hour. The immunoreaction was visualized using 3,39-diamino-
benzidine tetrahydrochloride dihydrate (DAB) with nickel inten-
sification (Vector Laboratories) as the chromogen. All incubations
and rinses were performed at room temperature with agitation
using an orbital shaker. The sections were mounted onto gelatin-
coated slides, dehydrated, cleared in xylene and coverslipped.
For stereological cell counts serial coronal sections (50 mm) were
cut through the substantia nigra using a cryostat. Two sets of
sections were prepared with each set consisting of 7–8 sections,
100 mm apart. One set of sections was stained with Nissl (cresyl
violet). Another set was processed for TH immunohistochemistry
as described above. The numbers of Nissl-stained or TH-
immunoreactive neurons in the substantia nigra pars compacta
were counted using the optical fractionator method in the Stereo
Investigator (v 4.35) software program (Microbrightfield, Burling-
ton, VT).
A qualitative examination was performed to analyze immuno-
reactivities of a-synuclein, malondialdehyde and nitrotyrosine.
The analysis was done using 7 sections per animal (n=5 per
group).
One set of serial sections (210 mm apart) immunostained using a
mouse antibody against the neuronal marker NeuN were
measured for areas of 3-NP-induced NeuN loss to determine the
lesion volume using the point-counting method and the cavalieri
principle as estimator in the same software program.
Statistical analysis
Data represent mean6standard error of means (SEM) from
groups of animals. Experimental analysis applied with one-way
ANOVA. When F values implied significance at a level p,0.05,
Student-Newman-Keul’s or Tukey–Kramer multiple comparison
tests was applied to determine where the differences among groups
arose. All statistical analysis was performed using the Graphpad
Instat software (GraphPad, San Diego, CA).
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